Cargando…

Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action

SIMPLE SUMMARY: Neuroblastoma is a malignant tumor of the sympathetic nervous system that causes aggressive disease in children. The overall survival rate of high-risk patients is very low, therefore developing effective and safe therapies for neuroblastoma is an urgent unmet medical need. The mouse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wei, Wang, Xinjie, Rajaei, Mehrdad, Youn, Ji Youn, Zafar, Atif, Deokar, Hemantkumar, Buolamwini, John K., Yang, Jianhua, Foster, Jennifer H., Zhou, Jia, Zhang, Ruiwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762001/ https://www.ncbi.nlm.nih.gov/pubmed/33291373 http://dx.doi.org/10.3390/cancers12123651

Ejemplares similares

Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action
por: Punganuru, Surendra R., et al.
Publicado: (2020)

Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy
por: Qin, Jiang-Jiang, et al.
Publicado: (2018)

Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy †
por: Wang, Wei, et al.
Publicado: (2020)

Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents
por: Patil, Shivaputra A, et al.
Publicado: (2017)

Molecular targeting therapies for neuroblastoma: Progress and challenges
por: Zafar, Atif, et al.
Publicado: (2020)

Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure–Activity Relationships, and Molecular Mechanisms of Action
por: Nag, Subhasree Ashok, et al.
Publicado: (2012)

Oral nano-delivery of anticancer ginsenoside 25-OCH(3)-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action
por: Voruganti, Sukesh, et al.
Publicado: (2015)

A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance
por: Wang, Wei, et al.
Publicado: (2019)

Experimental Therapy of Ovarian Cancer with Synthetic Makaluvamine Analog: In Vitro and In Vivo Anticancer Activity and Molecular Mechanisms of Action
por: Chen, Tao, et al.
Publicado: (2011)

Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation
por: Qin, Jiang-Jiang, et al.
Publicado: (2014)

The MDM2-p53 pathway revisited
por: Nag, Subhasree, et al.
Publicado: (2013)

Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA
por: Qin, Jiang-Jiang, et al.
Publicado: (2015)

ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo
por: Yu, Yang, et al.
Publicado: (2022)

Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action
por: Khan, Saman, et al.
Publicado: (2017)

Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma
por: Lu, Jiaxiong, et al.
Publicado: (2016)

Design, Preparation, and Evaluation of Osthol Poly-Butyl-Cyanoacrylate Nanoparticles with Improved In Vitro Anticancer Activity in Neuroblastoma Treatment
por: Zheng, Liqing, et al.
Publicado: (2022)

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
por: Van Goethem, Alan, et al.
Publicado: (2017)

Androgen Receptor Regulates the Growth of Neuroblastoma Cells in vitro and in vivo
por: Sun, Junyan, et al.
Publicado: (2017)

MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells
por: Gu, Lubing, et al.
Publicado: (2011)

MDM2- an indispensable player in tumorigenesis
por: Zafar, Aasma, et al.
Publicado: (2023)

KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology
por: Wang, Wei, et al.
Publicado: (2012)

Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation
por: Zhang, Zhuo, et al.
Publicado: (2008)

Anticancer potential of nitric oxide (NO) in neuroblastoma treatment
por: Gordon, Jenna L., et al.
Publicado: (2021)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

Ligand-Based and Docking-Based Virtual Screening of MDM2 Inhibitors as Potent Anticancer Agents
por: Li, Bing-Hui, et al.
Publicado: (2021)

Antitumor effect of Escherichia coli-derived outer membrane vesicles on neuroblastoma in vitro and in vivo : Effect of E. coli-OMVs on neuroblastoma
por: Jin, Liming, et al.
Publicado: (2022)

In Vitro Anticancer Activity and Mechanism of Action of an Aziridinyl Galactopyranoside
por: Burgos-Morón, Estefanía, et al.
Publicado: (2021)

The In Vitro and In Vivo Anticancer Properties of Moringa oleifera
por: Khor, Kang Zi, et al.
Publicado: (2018)

JKA97, a Novel Benzylidene Analog of Harmine, Exerts Anti-Cancer Effects by Inducing G1 Arrest, Apoptosis, and p53-Independent Up-Regulation of p21
por: Yang, Xinyi, et al.
Publicado: (2012)

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2019)

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
por: Martinez-Monleon, Angela, et al.
Publicado: (2022)

Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy
por: Qin, Jiang-Jiang, et al.
Publicado: (2016)

Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
por: Qin, Jiang-Jiang, et al.
Publicado: (2016)

Leflunomide Reduces Proliferation and Induces Apoptosis in Neuroblastoma Cells In Vitro and In Vivo
por: Zhu, Shunqin, et al.
Publicado: (2013)

MicroRNA-145 overexpression inhibits neuroblastoma tumorigenesis in vitro and in vivo
por: Zhao, Jing, et al.
Publicado: (2020)

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo
por: Flynn, Sean M., et al.
Publicado: (2019)

Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
por: Kon, Ning, et al.
Publicado: (2018)

Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine
por: Qin, Jiang-Jiang, et al.
Publicado: (2018)

Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment
por: Hoffman-Luca, C. Gianna, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e1qr63kp6r7goftcata8sgcasp